Try our Advanced Search for more refined results

UC Fights Teva's Bid To Invalidate Prostate Cancer Patent

By Alex Baldwin (June 14, 2023, 6:27 PM BST) -- The University of California has denied claims from Teva Pharmaceuticals that a key patent it owns for the blockbuster prostate cancer treatment Xtandi is invalid, firing back with its own allegations that the drug company intends to infringe the patent....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!